Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  NASDAQ OMX COPENHAGEN  >  Novo Nordisk A/S    NOVO B   DK0060534915


End-of-day quote. End-of-day quote NASDAQ OMX COPENHAGEN - 12/02
420.65 DKK   +0.88%
12/01NOVO NORDISK A/S : - Company announcements, trading in own shares
12/01NOVO NORDISK A/S : ESG presentation ()
12/01NOVO NORDISK : Gets a Buy rating from JP Morgan
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Novo Nordisk A/S : Bavarian Nordic Announces Appointment of Anu Helena Kerns as Executive Vice President, People and Organization

10/12/2020 | 10:05am EST

COPENHAGEN - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) announced today the appointment of Ms. Anu Helena Kerns to the position of Executive Vice President, People and Organization effective from November 2020.

In this newly established role, Ms. Kerns will drive the organizational development of Bavarian Nordic through the ongoing commercial transformation of the company. She will report to Paul Chaplin, President and CEO, and will join the Company's Executive Management Team.

Ms. Kerns brings more than 15 years of leadership experience driving human resource and communication strategies. She joins Bavarian Nordic after 11 years of tenure in Novo Nordisk where she has held various leadership roles with increasing responsibilities, including 5 years abroad where she was responsible for establishing a new regional organizational structure and driving the HR development and communication strategy. Prior to Novo Nordisk she worked for 8 years in the financial sector with employer branding, reputation management and change communication. Ms. Kerns holds a Master of Science in International Business Administration and Modern Languages from Copenhagen Business School.

'I am very pleased that we have managed to attract Anu and strengthen the Executive team. She brings a wealth of experience from her international and diverse career and will help us keeping people and organization high on the agenda on our continued journey to become one of the largest pure play vaccine companies,' said Paul Chaplin, President and CEO of Bavarian Nordic.

'I am incredibly excited to be joining Bavarian Nordic at this transformative stage of its development. I look forward to working with the Executive team and the rest of the organization, and to shaping a people and organization agenda that will help realize Bavarian Nordic's vision for the future,' said Anu Helena Kerns.

About Bavarian Nordic

Bavarian Nordic is a fully integrated biotechnology company focused on the development, manufacture and commercialization of life-saving vaccines. We are a global leader in smallpox vaccines and have been a long-term supplier to the U.S. Strategic National Stockpile of a non-replicating smallpox vaccine, which has been approved by the FDA under the trade name JYNNEOS, also for the protection against monkeypox. The vaccine is approved as a smallpox vaccine in Europe under the trade name IMVANEX and in Canada under the trade name IMVAMUNE. Our commercial product portfolio furthermore contains the market-leading vaccine Rabipur/RabAvert against rabies and Encepur against tick-borne encephalitis. Using our live virus vaccine platform technology, MVA-BN, we have created a diverse portfolio of proprietary and partnered product candidates designed to save and improve lives by unlocking the power of the immune system, including an Ebola vaccine, MVABEA, which is licensed to Janssen.


Rolf Sass Sorensen

Tel: +45 61 77 47 43

(C) 2020 Electronic News Publishing, source ENP Newswire

Stocks mentioned in the article
ChangeLast1st jan.
BAVARIAN NORDIC A/S -0.11% 184 Delayed Quote.7.44%
NOVO NORDISK A/S 0.88% 420.65 Delayed Quote.7.85%
All news about NOVO NORDISK A/S
12/01NOVO NORDISK A/S : - Company announcements, trading in own shares
12/01NOVO NORDISK A/S : ESG presentation ()
12/01NOVO NORDISK : Gets a Buy rating from JP Morgan
11/30Weight-Loss Firm Noom Names First CFO
11/23NOVO NORDISK A/S : – Share repurchase programme
11/20India's Gland Pharma jumps 23% in market debut
11/18NOVO NORDISK A/S : - Once-weekly semaglutide 2.0 mg demonstrates superior reduct..
11/18NOVO NORDISK A/S : Experts Urge Govt to Subsidise Cost of Diabetes Management, T..
11/17NOVO NORDISK A/S : Once-weekly semaglutide 2.0 mg demonstrates superior reductio..
11/16GILEAD SCIENCES : and Novo Nordisk Present New Data from Proof-of-Concept Trial ..
More news
Sales 2020 127 B 20 692 M 20 692 M
Net income 2020 42 174 M 6 849 M 6 849 M
Net cash 2020 8 472 M 1 376 M 1 376 M
P/E ratio 2020 23,0x
Yield 2020 2,16%
Capitalization 965 B 157 B 157 B
EV / Sales 2020 7,51x
EV / Sales 2021 7,05x
Nbr of Employees 44 326
Free-Float 75,1%
Duration : Period :
Novo Nordisk A/S Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NOVO NORDISK A/S
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus HOLD
Number of Analysts 27
Average target price 439,69 DKK
Last Close Price 417,00 DKK
Spread / Highest target 30,7%
Spread / Average Target 5,44%
Spread / Lowest Target -30,5%
EPS Revisions
Lars Fruergaard Jørgensen President & Chief Executive Officer
Helge Lund Chairman
Maziar Mike Doustdar Executive Vice President-International Operations
Karsten Munk Knudsen Chief Financial Officer & Executive Vice President
Mads Krogsgaard Thomsen Chief Science Officer & Executive Vice President
Sector and Competitors
1st jan.Capitalization (M$)
NOVO NORDISK A/S7.85%156 152
JOHNSON & JOHNSON1.08%388 168
ROCHE HOLDING AG-4.59%284 650
PFIZER, INC.6.17%219 056
MERCK & CO., INC.-10.34%206 324
NOVARTIS AG-11.46%205 415